Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
Moderna receives FDA approval for mFLUSIVA, a new seasonal flu vaccine for adults 50 and older, launching for the 2026-2027 virus season.
Moderna got permission to sell a new flu shot for older adults starting next year. This shows the company is growing beyond COVID vaccines, which matters because it means they're building new ways to make money for the future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.